Great to have the Spark Valuation to give us some baseline figures.
I see any valuation as being a fluid object. Perhaps if the valuation was to be released after the top line data from Phase ! and the granting of ODD and other near term events, then we might be looking at launching the projections off a higher base to give us a different endpoint valuation.
And the assumption of MPL only capturing 10% of the addressable market seems a bit light on to me, especially if we become the new standard of care.
But it is informative to view the factors involved in a valuation.
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3, page-31
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.020(8.89%) |
Mkt cap ! $81.16M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.5¢ | $331.9K | 1.617M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 440882 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 12736 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |